HCA Healthcare, Inc. (HCA)
HCA Healthcare owns and operates hospitals and other care facilities. At 31 December 2025 it ran 190 hospitals, made up of 179 general acute care hospitals, seven behavioral hospitals and four rehabilitation hospitals, along with 121 freestanding ambulatory surgery centres and 31 freestanding endoscopy centres. The facilities sit in 19 states and England. The company commenced operations in 1968 through its predecessors, was incorporated in Delaware in October 2010 and is based in Nashville, Tennessee.
Compare with another name What $10,000 in HCA Healthcare became Open in your desk ↗
Latest results
this quarterthe same quarter a year earlierHover a bar for its figure.
this yearthe year beforeHover a bar for its figure.
The years before, in words
HCA Healthcare (HCA) reported revenue of $75.6 billion for fiscal 2025, the year ended 31 December 2025, up 7.1% on the year before. Net income was $6.8 billion and diluted earnings per share $28.33. Revenue was $70.6 billion in fiscal 2024, $65.0 billion in fiscal 2023, $60.2 billion in fiscal 2022 and $58.8 billion in fiscal 2021. Net income in the same years was $5.8 billion, $5.2 billion, $5.6 billion and $7.0 billion. Over the twelve months to 30 September 2026, HCA Healthcare reported revenue of $78.7 billion and net income of $6.8 billion. Revenue grew 8.0% a year, compounded, over the five years to fiscal 2025. HCA Healthcare declared $3.06 a share in dividends over the last four quarters and had 211 million shares outstanding at the latest filed count. At 30 September 2026 it carried $50.5 billion of debt and $908 million of cash. At the close of 6 November 2026 the market cap of HCA Healthcare was $104.4 billion, 16.4 times its earnings over the last twelve months.Ratios
From the filings
At the close of 6 November 2026
29 ready-made ratios, from FCF yield to net debt to EBITDA, wait on the Formulas page, each with what it tells you. Browse and add them →
Read more
The priced ones use the latest price, the last regular-hours trade on IEX. Debt to equity here stands on the total debt HCA Healthcare, Inc. states in its own filing, with lease liabilities counted separately and never inside it. Nothing here is a valuation or a view.Read more
Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. Day by day for the last three years; before that one point a week, carrying the week's last close and its average daily volume, so a volume bar means the same thing across the whole series; the bars sit under the price on their own scale, on the right. The moving averages need consecutive days and are drawn from the daily part. P/E is the close over the trailing four quarters' EPS as filed at each filing date, on the current share count; the dashed line is the median over the range shown. Sales and margin are quarterly revenue and the operating margin from the tables above. EV/EBITDA, price to book and market cap to sales use the latest filed balance sheet and share count at each date. Before the quarters on file begin, P/E, price to book and market cap to sales stand on each annual report from the day it was filed. Drawn in your browser; the range and overlay you pick are remembered here only.Quarterly results
| Q4 FY2021 * | Q1 FY2022 | Q2 FY2022 | Q3 FY2022 | Q4 FY2022 * | Q1 FY2023 | Q2 FY2023 | Q3 FY2023 | Q4 FY2023 * | Q1 FY2024 | Q2 FY2024 | Q3 FY2024 | Q4 FY2024 * | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 * | Q1 FY2026 | Q2 FY2026 | Q3 FY2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 15,064 | 14,945 | 14,820 | 14,971 | 15,497 | 15,591 | 15,861 | 16,213 | 17,303 | 17,339 | 17,492 | 17,487 | 18,285 | 18,321 | 18,605 | 19,161 | 19,513 | 19,109 | 20,230 | 19,849 |
| Operating income | 2,586 | 1,814 | 1,760 | 1,704 | 3,302 | 1,922 | 1,809 | 1,630 | 2,345 | 2,247 | 2,237 | 1,906 | 2,133 | 2,327 | 2,415 | 2,418 | 2,672 | 2,287 | 2,494 | 2,370 |
| Operating margin | 17% | 12% | 12% | 11% | 21% | 12% | 11% | 10% | 14% | 13% | 13% | 11% | 12% | 13% | 13% | 13% | 14% | 12% | 12% | 12% |
| Interest expense | 398 | 408 | 434 | 446 | 453 | 479 | 485 | 483 | 491 | 512 | 506 | 515 | 528 | 547 | 568 | 561 | 572 | 584 | 599 | 607 |
| Pre-tax income | 2,586 | 1,814 | 1,760 | 1,704 | 3,302 | 1,922 | 1,809 | 1,630 | 2,345 | 2,247 | 2,237 | 1,906 | 2,133 | 2,327 | 2,415 | 2,418 | 2,672 | 2,287 | 2,494 | 2,370 |
| Tax rate | 22% | 19% | 22% | 21% | 20% | 20% | 22% | 22% | 21% | 20% | 25% | 22% | 21% | 22% | 22% | 21% | 19% | 19% | 23% | 22% |
| Net income | 1,814 | 1,273 | 1,155 | 1,134 | 2,081 | 1,363 | 1,193 | 1,079 | 1,607 | 1,591 | 1,461 | 1,270 | 1,438 | 1,610 | 1,653 | 1,643 | 1,878 | 1,620 | 1,699 | 1,579 |
| Net margin | 12% | 9% | 8% | 8% | 13% | 9% | 8% | 7% | 9% | 9% | 8% | 7% | 8% | 9% | 9% | 9% | 10% | 8% | 8% | 8% |
| Diluted EPS | $5.66 | $4.14 | $3.90 | $3.91 | $7.28 | $4.85 | $4.29 | $3.91 | $5.93 | $5.93 | $5.53 | $4.88 | $5.63 | $6.45 | $6.83 | $6.96 | $8.14 | $7.15 | $7.62 | $7.27 |
| Operating cash flow | 2,443 | 1,345 | 1,630 | 3,020 | 2,527 | 1,803 | 2,475 | 2,479 | 2,674 | 2,469 | 1,971 | 3,515 | 2,559 | 1,651 | 4,210 | 4,416 | 2,359 | 2,014 | 2,335 | 4,461 |
| Capital expenditure | 1,192 | 861 | 1,080 | 1,131 | 1,323 | 1,197 | 1,241 | 1,147 | 1,159 | 1,118 | 1,281 | 1,191 | 1,285 | 991 | 1,176 | 1,288 | 1,489 | 1,119 | 1,231 | 1,357 |
| Free cash flow | 1,251 | 484 | 550 | 1,889 | 1,204 | 606 | 1,234 | 1,332 | 1,515 | 1,351 | 690 | 2,324 | 1,274 | 660 | 3,034 | 3,128 | 870 | 895 | 1,104 | 3,104 |
| Buybacks | 2,072 | 2,101 | 2,682 | 698 | 1,519 | 846 | 915 | 1,140 | 910 | 1,180 | 1,367 | 1,795 | 1,700 | 2,506 | 2,505 | 2,498 | 2,558 | 1,571 | 2,064 | 2,970 |
| Dividends paid | 148 | 177 | 160 | 160 | 156 | 175 | 164 | 162 | 160 | 185 | 171 | 169 | 165 | 180 | 171 | 166 | 162 | 183 | 171 | 165 |
| Shares outstanding | 305m | 299m | 287m | 284m | 277m | 276m | 273m | 269m | 266m | 263m | 259m | 255m | 250m | 243m | 236m | 230m | 225m | 223m | 218m | 211m |
| Filing | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q |
Read more
* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A fourth quarter's EPS, and its diluted share count where shown, are from the company's results press release for that quarter, checked against the company's filed figures or a second data source. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.Income statement (profit and loss)
Read more
Each column runs from the last twelve months as filed to the year chosen in its heading, at a yearly rate. Sales growth starts at the company's own five-year rate and eases a third of the way each year toward the median of the 45 peers in Healthcare (13.2% a year), because a rate far from the rest rarely lasts. Before you open a year, the strip reads today's price backwards: the yearly sales growth that brings EPS, at the company's own margins, tax and share count, to today's price at the median P/E of the 33 peers in Healthcare (25.3). Low, middle, high opens three columns for one year: the low and high cases take the company's own weaker and stronger years in the table (the lower and upper quarter of its yearly sales growth and operating margin) and the lower and higher of today's P/E and its peers'; the middle is the boxes as they open. Net income keeps the share that went to minority holders; EPS is net income over the diluted shares, on the same basis as the EPS in the table. The price is that year's EPS at the P/E you set, and the yearly return runs from today's price to the year's end. These are your assumptions and your arithmetic, not an estimate of ours. The link carries your columns, so you can send the forecast to someone.| FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 41,490 | 43,614 | 46,677 | 51,336 | 51,533 | 58,752 | 60,233 | 64,968 | 70,603 | 75,600 | 78,701 |
| Operating income | 4,810 | 4,381 | 5,335 | 5,244 | 5,430 | 9,833 | 8,580 | 7,706 | 8,523 | 9,832 | 9,823 |
| Operating margin | 11.6% | 10.0% | 11.4% | 10.2% | 10.5% | 16.7% | 14.2% | 11.9% | 12.1% | 13.0% | 12.5% |
| Interest expense | 1,707 | 1,690 | 1,755 | 1,824 | 1,584 | 1,566 | 1,741 | 1,938 | 2,061 | 2,248 | 2,362 |
| Pre-tax income | 4,810 | 4,381 | 5,335 | 5,244 | 5,430 | 9,833 | 8,580 | 7,706 | 8,523 | 9,832 | 9,823 |
| Income tax | 1,378 | 1,638 | 946 | 1,099 | 1,043 | 2,112 | 1,746 | 1,615 | 1,866 | 2,050 | 2,024 |
| Effective tax rate | 28.6% | 37.4% | 17.7% | 21.0% | 19.2% | 21.5% | 20.3% | 21.0% | 21.9% | 20.9% | 20.6% |
| Net income | 2,890 | 2,216 | 3,787 | 3,505 | 3,754 | 6,956 | 5,643 | 5,242 | 5,760 | 6,784 | 6,776 |
| Net margin | 7.0% | 5.1% | 8.1% | 6.8% | 7.3% | 11.8% | 9.4% | 8.1% | 8.2% | 9.0% | 8.6% |
| Diluted EPS | $7.30 | $5.95 | $10.66 | $10.07 | $10.93 | $21.16 | $19.15 | $18.97 | $22.00 | $28.33 | $30.18 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
Read more
Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.Revenue by segment FY2016 to FY2025
| FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | Share of the parts, latest year | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| American Group | 19,670 | 20,912 | 21,959 | 23,173 | 23,593 | 19,636 | 20,858 | 22,318 | 24,668 | 26,445 | 35.0% |
| Atlantic Group | n/a | n/a | n/a | n/a | n/a | 19,098 | 19,324 | 21,167 | 23,380 | 24,709 | 32.7% |
| National Group | 19,845 | 20,772 | 22,581 | 25,913 | 25,694 | 16,329 | 16,767 | 18,105 | 19,656 | 21,278 | 28.1% |
| Corporate and Other | 1,975 | 1,930 | 2,137 | 2,250 | 2,246 | 3,689 | 3,284 | 3,378 | 2,899 | 3,168 | 4.2% |
$ billion; hover a block for its figure and share; a part named with years is one the company split its revenue into only then
Read more
Each year's figures come from the most recent 10-K that includes that year. A year is shown only where the parts add up to the revenue above. Fiscal years are labelled by the year they end in.Cash flow
Read more
The figure a share at the top is what a discounted cash flow calls intrinsic value, worked out on your assumptions. Everything after year five is one sum: the sixth year's cash, growing at the long-run rate every year after, added up and brought back to today's money. Each year runs from the last twelve months as filed. Sales growth opens where Play it forward does: the company's own five-year rate, easing a third of the way each year toward the median of the 45 peers in Healthcare (13.2% a year); change a year and the years after it follow. Operating cash flow, capital expenditure and share-based pay open at the company's own median share of sales over its last five years, shown under each row. Share-based pay is taken off because operating cash flow adds back the shares paid to staff as if they cost nothing; set it to 0 to leave it in. Capital spending counts every capital line the company files in its cash flow, such as equipment it leases to customers, software, wells or property it develops, named under the row, while the Capital expenditure row in the table below stays the one line as filed; buying a business, securities or a finished property is not counted. The discount rate opens at 10%, about what US stocks have returned a year over the long run, so it is the return you give up by holding this company instead of the market; the growth after year five opens at 3%, a little under the US economy's long-run growth in dollars, because no company outgrows it for ever. Net debt is the debt and short-term borrowings less the cash on the latest balance sheet that shows the debt; the figure per share divides what is left by the diluted share count. These are your assumptions and your arithmetic, not an estimate of ours. The link carries them, so you can send them to someone.| FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 5,653 | 5,426 | 6,761 | 7,602 | 9,232 | 8,959 | 8,522 | 9,431 | 10,514 | 12,636 | 11,169 |
| Capital expenditure | 2,760 | 3,015 | 3,573 | 4,158 | 2,835 | 3,577 | 4,395 | 4,744 | 4,875 | 4,944 | 5,196 |
| Free cash flow | 2,893 | 2,411 | 3,188 | 3,444 | 6,397 | 5,382 | 4,127 | 4,687 | 5,639 | 7,692 | 5,973 |
| Free cash flow margin | 7.0% | 5.5% | 6.8% | 6.7% | 12.4% | 9.2% | 6.9% | 7.2% | 8.0% | 10.2% | 7.6% |
| Cash from investing | -3,240 | -4,279 | -3,901 | -5,720 | -3,393 | -2,643 | -3,389 | -5,317 | -4,933 | -4,988 | -6,072 |
| Cash from financing | -2,508 | -1,061 | -3,075 | -1,771 | -4,677 | -6,655 | -5,656 | -4,094 | -4,582 | -8,550 | -5,182 |
| Depreciation and amortisation | 1,966 | 2,131 | 2,278 | 2,596 | 2,721 | 2,853 | 2,969 | 3,077 | 3,312 | 3,523 | 3,739 |
| Share-based compensation | 251 | 270 | 268 | 347 | 362 | 440 | 341 | 262 | 360 | 401 | 404 |
| Buybacks | 2,751 | 2,051 | 1,530 | 1,031 | 441 | 8,215 | 7,000 | 3,811 | 6,042 | 10,067 | 9,163 |
| Dividends paid | n/a | 0.0 | 487 | 550 | 153 | 624 | 653 | 661 | 690 | 679 | 681 |
| Dividend per share | n/a | n/a | $1.40 | $1.60 | $0.43 | $1.92 | $2.24 | $2.40 | $2.64 | $2.88 | $3.06 |
| Diluted shares, weighted | 396m | 372m | 355m | 348m | 344m | 329m | 295m | 276m | 262m | 239m | 217m |
| Shares outstanding at period end | 371m | 350m | 343m | 338m | 339m | 305m | 277m | 266m | 250m | 225m | 211m |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
Read more
The dividend per share is as declared. Diluted shares are the weighted average for the year; a falling count is the buybacks net of issuance. TTM sums the last four quarters; the share counts are the latest quarter's.Balance sheet
| FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Funded by | |||||||||||
| Shareholders' equity | -7,302 | -6,806 | -4,950 | -2,808 | 572 | -933 | -2,767 | -1,774 | -2,499 | -6,027 | -8,077 |
| Non-controlling interest | 1,669 | 1,811 | 2,032 | 2,243 | 2,320 | 2,422 | 2,694 | 2,834 | 3,054 | 3,256 | 3,478 |
| Debt | 31,376 | 33,058 | 32,821 | 33,722 | 31,004 | 34,579 | 38,084 | 39,593 | 43,031 | 46,492 | 50,493 |
| Operating lease liabilities | n/a | n/a | n/a | 1,499 | 1,673 | 1,755 | 1,752 | 1,903 | 1,863 | 1,853 | 1,933 |
| Finance lease liabilities | n/a | n/a | n/a | 470 | 494 | 577 | 579 | 541 | 624 | 625 | n/a |
| Other liabilities | 8,015 | 8,530 | 9,304 | 9,932 | 11,427 | 12,342 | 12,096 | 13,114 | 13,440 | 14,521 | 15,625 |
| Total liabilities and equity | 33,758 | 36,593 | 39,207 | 45,058 | 47,490 | 50,742 | 52,438 | 56,211 | 59,513 | 60,720 | 63,452 |
| Owned | |||||||||||
| Fixed assets | 16,352 | 17,895 | 19,757 | 22,715 | 23,199 | 24,063 | 25,575 | 27,715 | 29,414 | 31,141 | 32,268 |
| Investments | 385 | 472 | 409 | 462 | 504 | 541 | 381 | 477 | 569 | 485 | 463 |
| Cash and equivalents | 646 | 732 | 502 | 621 | 1,793 | 1,451 | 908 | 935 | 1,933 | 1,040 | 908 |
| Receivables | 5,826 | 6,501 | 6,789 | 7,380 | 7,051 | 8,095 | 8,891 | 9,958 | 10,751 | 10,867 | 11,509 |
| Inventory | 1,503 | 1,573 | 1,732 | 1,849 | 2,025 | 1,986 | 2,068 | 2,021 | 1,738 | 1,652 | 1,670 |
| Other assets | 9,046 | 9,420 | 10,018 | 12,031 | 12,918 | 14,606 | 14,615 | 15,105 | 15,108 | 15,535 | 16,634 |
| Total assets | 33,758 | 36,593 | 39,207 | 45,058 | 47,490 | 50,742 | 52,438 | 56,211 | 59,513 | 60,720 | 63,452 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
Read more
Both totals are the company's own. Other liabilities is the filed total less the rows above it: payables, deferred revenue, taxes, borrowings the rows above do not carry and the rest; other assets is the same on the other side. Investments add the current and non-current lines as filed. Debt is the company's own stated total where it files one, otherwise its long-term debt with the current maturities, never parts added together. A row is left blank in a year where the lines shown overlap and the remainder would fall below nil.Compounded growth
| 10 years | 5 years | 3 years | TTM | |
|---|---|---|---|---|
| Sales growth, compounded | n/a | 8.0% | 7.9% | 5.8% |
| Profit growth, compounded | n/a | 12.6% | 6.3% | 6.8% |
| Return on equity, average | n/a | n/a | n/a | n/a |
Read more
Return on equity is net income over shareholders' equity at each year end, averaged over the window (the TTM column is the latest year alone); equity is the parent's shareholders' equity as tagged in the 10-K. Arithmetic on filed numbers, nothing forecast.Questions
What was HCA Healthcare's revenue in fiscal 2025?
HCA Healthcare (HCA) reported revenue of $75.6 billion for fiscal 2025, the year ended 31 December 2025, up 7.1% on the year before.
How much did HCA Healthcare earn in fiscal 2025?
Net income was $6.8 billion for fiscal 2025, and diluted earnings per share $28.33.
What is HCA Healthcare's P/E ratio?
At the close of 6 November 2026, HCA Healthcare traded at 16.4 times its earnings over the twelve months to 30 September 2026.
What is HCA Healthcare's market cap?
The market cap of HCA Healthcare was $104.4 billion at the close of 6 November 2026.
Does HCA Healthcare pay a dividend?
Yes. HCA Healthcare declared $3.06 a share in dividends over the four quarters to 30 September 2026.
Peers: Healthcare
| Company | Market cap | P/E | ROE | Op. margin | Sales growth TTM | Debt to equity | Div. yield |
|---|---|---|---|---|---|---|---|
| HCA Healthcare, Inc. HCA | $104.4 billion | 16.40 | n/a | 12.5% | 5.8% | n/a | 0.6% |
| Natera, Inc. NTRA | $44.9 billion | n/a | -8.8% | -9.0% | 37.4% | 0.04 | n/a |
| Labcorp Holdings Inc. LH | $29.8 billion | 30.08 | 11.3% | 10.3% | 6.0% | 0.66 | 0.8% |
| Quest Diagnostics Inc. DGX | $28.1 billion | 25.46 | 14.8% | 14.6% | 9.1% | 0.73 | 1.3% |
| Tenet Healthcare Corp. THC | $22.6 billion | 8.22 | 53.3% | 24.4% | 6.2% | 2.43 | n/a |
| Guardant Health, Inc. GH | $20.4 billion | n/a | n/a | -39.4% | 41.7% | n/a | n/a |
| Encompass Health Corp. EHC | $13.5 billion | 21.49 | 24.0% | 18.3% | 9.4% | 0.97 | 0.6% |
| BrightSpring Health Services, Inc. BTSG | $13.4 billion | 36.31 | 18.8% | 3.4% | 22.9% | 1.00 | n/a |
| Universal Health Services Inc. UHS | $11.3 billion | 8.18 | 19.2% | 10.8% | 8.0% | 0.75 | 0.4% |
| Surgery Partners, Inc. SGRY | $3.0 billion | n/a | -5.3% | 11.4% | 4.0% | 2.25 | n/a |
| Ardent Health, Inc. ARDT | $2.4 billion | 16.79 | 10.5% | 4.5% | 2.0% | 0.79 | n/a |
| Community Health Systems Inc. CYH | $311 million | 8.48 | n/a | 10.9% | -7.8% | n/a | n/a |
All 59 in Healthcare
| Company | Market cap | P/E | ROE | Op. margin | Sales growth TTM | Debt to equity | Div. yield |
|---|---|---|---|---|---|---|---|
| HCA Healthcare, Inc. HCA | $104.4 billion | 16.40 | n/a | 12.5% | 5.8% | n/a | 0.6% |
| Natera, Inc. NTRA | $44.9 billion | n/a | -8.8% | -9.0% | 37.4% | 0.04 | n/a |
| Labcorp Holdings Inc. LH | $29.8 billion | 30.08 | 11.3% | 10.3% | 6.0% | 0.66 | 0.8% |
| Quest Diagnostics Inc. DGX | $28.1 billion | 25.46 | 14.8% | 14.6% | 9.1% | 0.73 | 1.3% |
| Tenet Healthcare Corp. THC | $22.6 billion | 8.22 | 53.3% | 24.4% | 6.2% | 2.43 | n/a |
| Guardant Health, Inc. GH | $20.4 billion | n/a | n/a | -39.4% | 41.7% | n/a | n/a |
| Encompass Health Corp. EHC | $13.5 billion | 21.49 | 24.0% | 18.3% | 9.4% | 0.97 | 0.6% |
| BrightSpring Health Services, Inc. BTSG | $13.4 billion | 36.31 | 18.8% | 3.4% | 22.9% | 1.00 | n/a |
| Davita Inc. DVA | $12.1 billion | 14.09 | n/a | 15.0% | 6.4% | n/a | n/a |
| Universal Health Services Inc. UHS | $11.3 billion | 8.18 | 19.2% | 10.8% | 8.0% | 0.75 | 0.4% |
| Ensign Group, Inc. ENSG | $10.6 billion | 26.96 | 15.6% | 9.0% | 17.5% | 0.08 | 0.1% |
| Pacs Group, Inc. PACS | $7.9 billion | 28.81 | 22.9% | 7.4% | 12.4% | 0.22 | n/a |
| Caris Life Sciences, Inc. CAI | $7.2 billion | 76.45 | 15.0% | 13.4% | n/a | 0.61 | n/a |
| Chemed Corp. CHE | $6.9 billion | 25.27 | 32.8% | 13.9% | 5.2% | 0.27 | 0.5% |
| Hims & Hers Health, Inc. HIMS | $6.1 billion | n/a | -43.8% | -6.0% | 28.0% | 4.21 | n/a |
| RadNet, Inc. RDNT | $6.0 billion | n/a | -1.9% | 3.1% | 18.9% | 1.22 | n/a |
| BillionToOne, Inc. BLLN | $5.4 billion | 104.29 | 8.7% | 10.2% | n/a | 0.16 | n/a |
| Grail, Inc. GRAL | $5.4 billion | n/a | -16.6% | -347.3% | 17.5% | 0.00 | n/a |
| Concentra Group Holdings Parent, Inc. CON | $5.3 billion | 24.96 | 42.7% | 16.9% | 11.8% | 3.00 | 0.6% |
| LifeStance Health Group, Inc. LFST | $5.2 billion | 72.47 | 4.8% | 6.2% | 22.6% | 0.18 | n/a |
| Option Care Health, Inc. OPCH | $4.7 billion | 22.77 | 16.2% | 5.9% | 4.0% | 0.87 | n/a |
| Sotera Health Co. SHC | $4.6 billion | 26.68 | 23.7% | n/a | 6.9% | 2.91 | n/a |
| CareDx, Inc. CDNA | $4.1 billion | 32.86 | 27.5% | 23.4% | 38.9% | 0.00 | n/a |
| Acadia Healthcare Company, Inc. ACHC | $3.4 billion | n/a | -55.8% | -31.7% | 4.5% | 1.16 | n/a |
| National Healthcare Corp. NHC | $3.3 billion | 28.76 | 10.2% | 9.8% | 5.6% | 0.45 | 1.3% |
| Privia Health Group, Inc. PRVA | $3.1 billion | 93.92 | 4.3% | 2.1% | 19.2% | 0.00 | n/a |
| Surgery Partners, Inc. SGRY | $3.0 billion | n/a | -5.3% | 11.4% | 4.0% | 2.25 | n/a |
| Aveanna Healthcare Holdings, Inc. AVAH | $2.9 billion | 10.76 | 95.6% | 10.5% | 19.5% | 4.52 | n/a |
| Progyny, Inc. PGNY | $2.6 billion | 31.96 | 22.0% | 9.4% | 5.5% | 0.00 | n/a |
| Pediatrix Medical Group, Inc. MD | $2.4 billion | 17.00 | 17.7% | 10.9% | 1.9% | 0.68 | n/a |
| Ardent Health, Inc. ARDT | $2.4 billion | 16.79 | 10.5% | 4.5% | 2.0% | 0.79 | n/a |
| Addus HomeCare Corp. ADUS | $2.3 billion | 20.70 | 9.4% | 10.3% | 11.5% | 0.02 | n/a |
| Brookdale Senior Living Inc. BKD | $2.2 billion | n/a | n/a | 6.8% | -8.4% | n/a | n/a |
| Fortrea Holdings Inc. FTRE | $2.1 billion | n/a | -12.9% | 0.5% | -3.4% | 1.98 | n/a |
| Veracyte, Inc. VCYT | $1.9 billion | 15.56 | 8.9% | 17.1% | 17.5% | 0.00 | n/a |
| agilon health, Inc. AGL | $1.9 billion | 20.59 | -31.0% | -2.6% | 2.0% | 0.11 | n/a |
| GeneDx Holdings Corp. WGS | $1.9 billion | n/a | -43.5% | -20.3% | 25.4% | 0.41 | n/a |
| Personalis, Inc. PSNL | $1.7 billion | n/a | -56.1% | -156.7% | 16.9% | n/a | n/a |
| Healthcare Services Group Inc. HCSG | $1.6 billion | 16.29 | 19.7% | n/a | 4.0% | 0.00 | n/a |
| Teladoc Health, Inc. TDOC | $1.6 billion | n/a | -12.0% | -6.6% | -2.4% | 0.77 | n/a |
| Sonida Senior Living, Inc. SNDA | $1.6 billion | n/a | -14.8% | -11.8% | 70.0% | 1.88 | n/a |
| U S Physical Therapy Inc. USPH | $1.5 billion | n/a | 7.0% | 9.1% | 10.4% | 0.57 | 1.8% |
| Lumexa Imaging Holdings, Inc. LMRI | $1.3 billion | n/a | n/a | n/a | n/a | 1.36 | n/a |
| Pennant Group, Inc. PNTG | $1.3 billion | 36.73 | 8.5% | 5.8% | 38.7% | 0.47 | n/a |
| InnovAge Holding Corp. INNV | $1.2 billion | 149.67 | 3.5% | 1.4% | 15.1% | 0.19 | n/a |
| Castle Biosciences Inc. CSTL | $1,000 million | n/a | -4.8% | -7.4% | 9.8% | 0.02 | 0.0% |
| AdaptHealth Corp. AHCO | $999 million | n/a | -33.2% | -11.5% | -3.2% | 1.54 | n/a |
| Omada Health, Inc. OMDA | $936 million | 71.90 | 5.1% | 2.1% | n/a | 0.00 | n/a |
| Starling Oncology, Inc. STLN | $682 million | n/a | n/a | -3.4% | 34.6% | n/a | n/a |
| Fulgent Genetics, Inc. FLGT | $660 million | n/a | -9.2% | -39.2% | 4.7% | 0.00 | n/a |
| SBC Medical Group Holdings Inc. SBC | $522 million | 10.83 | 18.6% | 37.3% | -6.9% | 0.14 | n/a |
| Viemed Healthcare, Inc. VMD | $348 million | 24.05 | 10.4% | 7.8% | 21.8% | 0.03 | n/a |
| Community Health Systems Inc. CYH | $311 million | 8.48 | n/a | 10.9% | -7.8% | n/a | n/a |
| Exagen Inc. XGN | $141 million | n/a | -154.9% | -18.6% | 20.8% | 1.87 | n/a |
| LifeMD, Inc. LFMD | $113 million | n/a | n/a | n/a | n/a | 0.00 | n/a |
| Sera Prognostics, Inc. SERA | $112 million | n/a | -63.8% | -38,755.2% | 1.1% | 0.00 | n/a |
| Park Dental Partners, Inc. PARK | $94 million | n/a | n/a | n/a | n/a | 0.37 | n/a |
| Biodesix Inc. BDSX | $94 million | n/a | -312.1% | -18.7% | 31.2% | 5.76 | n/a |
| Airsculpt Technologies, Inc. AIRS | $39 million | n/a | -8.9% | -4.7% | -6.3% | 0.35 | n/a |
Read more
By market capitalisation; a click on a heading sorts by it, largest first, and a second click turns it round. Each figure is the same arithmetic as the ratio box above, on each company's own filings and latest close; a name marked * is a foreign company that files once a year, on its latest fiscal year.The public record on HCA
| Dividends | $3.06 a share over the four quarters to 30 September 2026, a 0.62% yield |
| Filings | 21 in twelve months: 13 current reports (8-K), about 9 other events; 5 results of operations; 5 regulation FD disclosure; 3 new financial obligation; 2 material agreement |
| Planned insider sales | 7 Form 144 notices in twelve months, $49.8 million; latest 4 November 2026 |
| Options tape | put/call 1.2 by open interest at the 6 November 2026 close; the straddle prices a 5.7% move to 20 November 2026 |
| 13F holders | 1,348 funds reported a position for the quarter to 30 June 2026; largest BlackRock, Inc. |
| Insider trading | 21 sales and 0 purchases on Form 4 in twelve months |
| Congress | 1 House trade disclosed in six months |
| Short interest | 4.9 million shares short, 4.60 days to cover at 15 October 2026 |
| Documents | the 10-K, the 10-Qs, the proxy and 5 earnings press releases, each linked |
Filings
| Filing | Period | Filed | Where |
|---|---|---|---|
| 10-Q | 30 September 2026 | 29 October 2026 | EDGAR |
| 10-Q | 30 June 2026 | 28 July 2026 | EDGAR |
| 10-Q | 31 March 2026 | 29 April 2026 | EDGAR |
| 10-K | 31 December 2025 | 10 February 2026 | EDGAR |
| 10-Q | 30 September 2025 | 30 October 2025 | EDGAR |
| 10-Q | 30 June 2025 | 4 August 2025 | EDGAR |
| 10-Q | 31 March 2025 | 1 May 2025 | EDGAR |
| 10-K | 31 December 2024 | 14 February 2025 | EDGAR |
| 10-Q | 30 September 2024 | 31 October 2024 | EDGAR |
| 10-Q | 30 June 2024 | 29 July 2024 | EDGAR |
Reading about a stock somewhere else? Our free Chrome extension, GreekSoup Stock Ticker Lookup: Earnings, Insider Trades, 13F Holders, shows the latest quarter against a year ago, insider trades and 13F holders when you hover a $ticker such as $AAPL.